The glycosyl-phosphatidylinositol (GPI) anchor of the Trypanosoma brucei variant surface glycoprotein (VSG) is unique in having exclusively myristate as its fatty acid component. We previously demonstrated that the myristate specificity is the result of two independent pathways. First, the newly synthesized free GPI, which is not myristoylated, undergoes fatty acid remodeling to (1) . Since the parasite genome encodes a repertoire of up to 1000 different VSGs, the mammalian immune system, always one step behind, is continually presented with parasites expressing different VSGs. This trypanosome strategy has thwarted the development of a vaccine to prevent trypanosomiasis.
African trypanosomes, the protozoan parasites responsible for sleeping sickness, are cloaked with a dense protein coat composed of 107 identical variant surface glycoprotein (VSG) molecules. By using a sophisticated system of antigenic variation, these bloodstream parasites can change expression of their VSG to that of another with a different amino acid sequence (1) . Since the parasite genome encodes a repertoire of up to 1000 different VSGs, the mammalian immune system, always one step behind, is continually presented with parasites expressing different VSGs. This trypanosome strategy has thwarted the development of a vaccine to prevent trypanosomiasis.
The Trypanosoma brucei VSG is attached to the parasite plasma membrane through a glycosyl-phosphatidylinositol (GPI) anchor. A unique feature of this GPI is that it contains exclusively myristate (a 14-carbon, saturated fatty acid) as its lipid moiety (2) . The reason for the choice of myristate is not yet understood, but its presence on the GPI led to the discovery that analogs of myristate are selectively toxic to these parasites and therefore are candidate antitrypanosomal agents (3, 4) .
The T brucei GPI biosynthetic pathway involves sequential construction of the ethanolamine-P-Man3-GlcN glycan core on phosphatidylinositol to form a GPI known as glycolipid A' (5) . This GPI then acquires its myristate by a specific fatty acid remodeling pathway involving sequential deacylation and reacylation (6) . The product, a dimyristoylated GPI known as glycolipid A, is linked to the newly synthesized VSG in the endoplasmic reticulum (ER). We recently discovered that trypanosomes have a second GPI myristoylation pathway known as myristate exchange (7) . In ,[l of chloroform/methanol/water (10:10:3, vol/vol) and treated as described for cell-free system labelings (7).
Labeling of the Cell-Free System with [3lH]Myristoyl-CoA.
The cell-free system was prepared and labeled as described (7 (Fig. 1C) . Finally, we used T brucei GPI-specific phospholipase C (GPI-PLC) (13) . Glycolipid samples were processed as described with absolute dpm calculated from scanner cpm using a standard curve (7) . VSG samples were precipitated/extracted with chloroform/methanol ( Fig. 2A but in the presence of inhibitors. Glycolipid A (-; 1.5 x 107 cell equivalents per sample) was analyzed by TLC and scanning. VSG (N; 5 x 107 cell equivalents per sample) was analyzed by SDS/PAGE (10% minigel). After fluorography, the VSG bands were cut out of the gel. These dried gel slices were rehydrated with 400 ,ul of water and then shaken at 37°C overnight with 325 ,ul of Protosol (DuPont/NEN) and 4 ml of Formula-963 scintillation fluid (DuPont/NEN). Radioactivity was quantitated by scintillation spectrometry. It should be noted that the concentration dependence of inhibition varies slightly with different lysates, and so all the conditions in this experiment were performed with the same lysate at the same time. Bars: 1, control; 2, 2 mM CdC12; 3, 1 mM CdC12; 4, 2 mM Al,(SO4)3; 5, 0.5 mM Al2(SO4)3; 6, 10 mM EDTA and 10 mM EGTA. change occurs on mature VSG as well as on newly synthesized VSG. To distinguish between these forms, we pretreated the cells for 90 min with tunicamycin, a drug that blocks N-linked glycosylation. We had shown previously that VSG synthesized after this treatment does not become N-glycosylated (as assayed by SDS/PAGE) and that tunicamycin does not change the kinetics of VSG transport through the secretory pathway (11, 15) . The newly synthesized VSG appears smaller (55 kDa) than mature VSG (57 kDa). When we added cycloheximide together with [3H]myristate, we observed exchange labeling of both 55-and 57-kDa VSG (Fig. 4A Bottom) , indicating that mature as well as newly synthesized VSG undergoes exchange. When we added cycloheximide earlier (-15 or -30 min), there was a gradual decrease in labeling of the 55-kDa protein, but there was little or no effect on labeling of the 57-kDa VSG (Fig.  4A, middle) . The decrease in labeling of 55-kDa VSG must be due to depletion of VSG in the secretory pathway by cycloheximide treatment. When we added cycloheximide at -45 min, labeling of 55-kDa VSG was abolished, but again there was no effect on labeling of mature 57-kDa VSG (Fig. 4A,  Top) . Densitometry of the fluorographs shown in Fig. 4A and from similar experiments confirmed that the amount of 57-kDa VSG labeled is independent of the time cycloheximide is added.
In a control experiment, we evaluated whether the 55-kDa species is in fact unglycosylated VSG. We used peptide-Nglycosidase F, an enzyme that removes N-linked glycans, to digest a sample from cells that had been preincubated for 45 min with tunicamycin and then labeled for 40 min with [3H]myristate in the presence of cycloheximide. We found that peptide-N-glycosidase F reduced the molecular mass of the 57-kDa VSG to 55 kDa (Fig. 4B) For this experiment we exploited the endogenous trypanosome GPI-specific phospholipase C (GPI-PLC), an enzyme that cleaves the dimyristoylglycerol from VSG's GPI anchor and thus removes the [3H]myristate label. Hypotonic lysis of trypanosomes activates this enzyme, resulting in cleavage of all of the surface VSG; however, VSG in the secretory pathway is protected from cleavage (11, 18) . We can therefore use hypotonic lysis to determine if myristate exchange into VSG occurs at the plasma membrane. If exchange were to take place on the plasma membrane, then exchange-labeled VSG would be cleaved by GPI-PLC upon hypotonic lysis. Fig. 5 shows the metabolic labeling of VSG with [3H]myristate in the presence of cycloheximide. Cells were hypotonically lysed on ice and then inhibited for 5 min at 37°C in the presence or absence ofp-chloromercuriphenylsulfonic acid, an inhibitor of GPI-PLC, prior to precipitation of the VSG. Almost all of the [3H]myristoylated VSG was protected from cleavage by GPI-PLC for up to 10 min. By 10 min, VSG starts reaching the plasma membrane and is cleaved; hence, the small difference between the two curves. This experiment shows that myristate exchange does not take place on the cell surface, because VSG labeled by exchange is protected from GPI-PLC cleavage during hypotonic lysis.
DISCUSSION
We previously identified two distinct myristoylation pathways for glycolipid A, the GPI precursor. The first, fatty acid remodeling, involves a sequential replacement of the longer fatty acids on glycolipid A' (the unremodeled product of the GPI biosynthetic pathway) with myristate (6). The second pathway, myristate exchange, involves trading one myristate for another at both positions of preexisting glycolipid A (7). Although exchange could be a relatively trivial reaction, if it simply exploited the remodeling machinery, we presented evidence that they are independent pathways (e.g., they apparently occur in different subcellular compartments, and they have different susceptibilities to inhibitors). The subcellular fractionation showed that exchange on glycolipid A does not occur in the ER and therefore must occur downstream of the ER (7). Since it seemed surprising that the trypanosome would have enzymatic machinery whose function was to myristoylate glycolipid A that had escaped the ER, we explored in the current study the possibility that the major substrate for myristate exchange is VSG protein.
Since VSG receives a myristoylated GPI anchor within 30 sec after synthesis of the polypeptide (11), we reasoned that de novo GPI anchoring of VSG would be inhibited in cells treated with cycloheximide. Under these conditions, we found that there was substantial [3H]myristate incorporation into VSG (Fig. 1A) . This incorporation must be by myristate exchange, and the difference between incorporation in the absence and Aii-"Ili.& in the presence of cycloheximide must be due to de novo anchor attachment (dashed line in Fig. 1A) .
It was surprising that exchange leveled off in Fig. 1A (Fig. 2) . The similar sensitivity to inhibitors of exchange labeling of VSG and glycolipid A (Fig. 3) is consistent with the notion that the same enzymatic machinery is responsible for labeling both substrates.
We were surprised to find that not only newly synthesized VSG but also mature VSG is a substrate for myristate exchange. To distinguish between these two VSG populations, we preincubated the cells with tunicamycin, an inhibitor of N-glycosylation. Mature VSG, which has two N-linked oligosaccharides (16) , has an apparent molecular mass of 57 kDa. In contrast, VSG synthesized in the presence of tunicamycin, and therefore missing these oligosaccharides, has an apparent molecular mass of 55 kDa. The unexpected labeling of mature VSG by myristate exchange (Fig. 4) raised the possibility that exchange could take place at or kinetically near the plasma membrane. We tested this hypothesis with a hypotonic lysis experiment, using the fact that cell surface VSG is cleaved by an endogenous GPI-PLC upon hypotonic lysis of the trypanosomes. In contrast, intracellular VSG is protected from this enzyme and thus retains its [3Hlmyristate label (2, 11, 15) . We found that VSG labeled by myristate exchange remains fully protected from cleavage for about 10 min (Fig. 5) tThis figure is based on the cross-sectional area of a VSG molecule [600 A2 (24) ] and the cross-sectional area of a phospholipid [40 A2 (25) ].
